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ORIGINAL ARTICLE
Expectations, concerns, and needs of patients who start drugs for chronic
conditions. A prospective observational study among community
pharmacies in Serbia
Katarina M. Vucicevica, Branislava R. Miljkovica, Bojana C. Golubovica, Marija N. Jovanovica,
Sandra D. Vezmar Kovacevica, Milica D. Culafica, Milena M. Kovacevica and Johan J. de Gierb
aDepartment of Pharmacokinetics and Clinical Pharmacy, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia; bDepartment
of Pharmacotherapy and Pharmaceutical Care, University of Groningen, Groningen, The Netherlands
KEY MESSAGES
 Patients prescribed new medicines for long-term conditions have interests, expectations, and concerns
about adverse reactions.
 During therapy initiation, one-fifth of these patients experienced practical problems and around a quarter
of patients reports adverse drug reactions.
ABSTRACT
Background: During the initiation of treatment of a chronic disease, patients may have varying
interests, expectations, concerns, and reasons to stop treatment, influencing compliance with
prescribed treatment. Thus, healthcare professionals are expected to integrate these needs into
medicines management.
Objectives: To determine what information is important to patients; assess predictors of
patients’ interests, expectations, concerns, reasons to stop therapy; evaluate drug-related prob-
lems following initiation of therapy and summarize how pharmacists resolve them during
patient–pharmacist counselling.
Methods: In 2014, a four-month study was performed in Serbian community pharmacies, as part
of the Pharmaceutical Care Quality Indicators Project led by the European Directorate for the
Quality of Medicines & Healthcare. Seventy community pharmacists were asked to participate in
the study. Pharmacists recruited adult patients who consented to participate in the study and
who initiated treatment, lasting at least six months. Patients completed an open-ended ques-
tions form. After two-to-four weeks, a patient–pharmacist consultation was performed.
Results: Forty-four community pharmacists (response rate 62.9%) sent back the completed forms
from 391 patients (response rate 67.1%). The total number of dispensed drugs was 403. In terms
of drug safety, 29.4% of patients sought information, 32.5% expressed concerns, and 28.1% of
patients cited it as a reason to discontinue treatment. During the first weeks of therapy, 18% of
patients experienced practical problems, while 27.3% reported adverse drug reactions.
Conclusion: Safety issues are a major focus of patients’ prescribed new medicines for long-term
treatment.
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Patient-centred services in community pharmacy set-
tings are still developing. However, in different coun-
tries, various pharmacists’ activities are implemented,
leading to the optimal medication therapy outcomes,
efficient management of the resources, safer drug use,
improvement in the quality of life, and lower hospital
admission rates [1–6].
Introducing new medicines for long-term treatment
is a critical moment for patients. Consequently, it is
important that healthcare professionals perceive and
respond to the needs of patients [7]. According to the
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previous reports, 30–50% of medicines are not taken
as recommended [8–10]. Patients benefit from infor-
mation and counselling on the disease, medicines as
well as treatment outcomes, to anticipate appropriate
drug use [10–12]. The ability for a patient to retain
information about a new medication can be limited by
a patient’s capacity to remember information given
during the consultations with the prescribing phys-
ician. Pharmacists are well positioned within a health-
care team to ensure that patient needs are met
[13,14]. Previous studies have shown that community
pharmacists can successfully intervene when a patient
is prescribed a new medicine(s) for a chronic condition
[4,15,16]. Hence, in more than 90% of community
pharmacies in England a basic service is provided to
the patients to whom new medicines are prescribed
[7,10,17,18].
The Committee of Experts on Quality and Safety
Standards in Pharmaceutical Practices and Care coordi-
nated by the European Directorate for the Quality of
Medicines & Healthcare (EDQM, Council of Europe) ini-
tiated a research programme. A questionnaire was
developed regarding delivery of pharmaceutical care
service in community pharmacies for patients receiving
newly prescribed long-term drugs. The concept of
pharmaceutical care focuses on the individual patient’s
needs and achieving positive therapy outcomes. These
are accomplished by steps that include: establishing
pharmacist–patient relationship; collecting relevant
information directly from the patient or the medical
records; identifying potential/actual drug-related prob-
lems; developing and implementing a therapy plan
together with a patient that will prevent/resolve drug-
related problems; and further monitoring and (if
needed) modifying the plan so desired therapy out-
comes are achieved. The Pharmaceutical Care Quality
Indicators Project (PCQIP) was carried out among
European countries in 2013–2014 [1,19,20]. It focused
on the previously described four steps. The pharma-
ceutical care concept is well known in the Serbian
pharmaceutical sector due to a high interest in post-
graduate education programmes of Pharmaceutical
Care at the University of Belgrade—Faculty of
Pharmacy during the last decade [21]. However,
pharmaceutical care practice is not consistent among
different pharmacies, as the national regulatory body
does not formally recognize those services.
The aim of this study was to determine what infor-
mation is relevant to patients receiving new medicines
for chronic treatment. Furthermore, to assess predic-
tors of patients’ interests (knowledge), expectations,
concerns, reasons to stop therapy, and drug-related




This prospective observational study was conducted in
the Serbian community pharmacies during a four-
month period in 2014 as a part of the PCQIP. Hence,
all stages of the research were performed in compli-
ance with EDQM study plans and protocols [1,19,20].
The local ethical committee of the University of
Belgrade—Faculty of Pharmacy approved this study
(no. 2718/2, 18 December 2013).
Recruitment of pharmacists and selection of
patients
The Pharmaceutical Chamber of Serbia announced the
study on their website and in the official journal and
performed recruitment of the community pharmacists.
Seventy community pharmacists applied to participate
in the study. Each pharmacist was asked to complete,
sign an agreement form and to recruit 5–10 adult
patients. Inclusion criteria were patient’s age 18–65
years, who initiated treatment with drugs for alimen-
tary tract and metabolism, cardiovascular, musculoskel-
etal, respiratory system, lasting at least six months and
not used in the previous period. Exclusion criteria
included no direct contact with the patient, physically
frail elderly, patients receiving palliative care or with
cognitive impairment. Each patient was informed
about the purpose of the study before signing the
consent form.
Data collection forms
All documents were originally developed by EDQM in
the English language. Translation and validation proce-
dures were applied including the process of forward
and backward translations, review of the translated
questions and their testing in a smaller group.
Patients, who gave informed consent, were asked
to complete ‘My checklist’ self-completion concord-
ance form (SCCF) at home [1,2,20]. This form allowed
patients to write down information they needed to
know, expectations and concerns they had, possible
reasons for therapy discontinuation, observed drug-
related problems during the first weeks of drug use or
any other issues in relation to newly started
medicines.
The patient–pharmacist consultation was appointed
after two-to-four weeks, and it was directed to the
issues reported in SCCF.
Finally, the pharmacists filled ‘Consultation form
for pharmacists,’ where they briefly recorded the
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feedbacks from patients’ answers in SCCFs and pro-
vided an overall evaluation and the consultation out-
come [1,2,20].
Outcomes and statistical analysis
The patients’ responses were summarized into several
categories and sub-categories (Table 1). The binary
coding system was used for numerical transformation
of patients’ answers. Descriptive and statistical analy-
ses using binomial logistic regression were performed
with IBM SPSS Statistics 18. Data was analysed as a
single cohort and per each group according to the
Anatomical Therapeutic Chemical Classification System
of newly prescribed drugs. Tested covariates were the
number of newly prescribed drugs and pharmacology
group/individual drug(s) and a model with a constant
was built using the backward Wald method. The
results of the analysis were presented as odds ratios
(OR) and their 95% confidence intervals (95%CI).
Statistical significance was considered at P< 0.05.
Results
In total, 44 community pharmacists (response rate
62.9%) sent back completed data forms from 391
patients (patients’ response rate 67.1%). The total num-
ber of dispensed drugs of interest was n¼ 403, includ-
ing cardiovascular (n¼ 247), alimentary tract (n¼ 59),
musculoskeletal (n¼ 37), and respiratory drugs (n¼ 60).
Interests (knowledge)
Most patients (84.9%) were interested in receiving
drug information beyond what they knew at the
moment the drug was dispensed. Mainly, patients
were interested in safety profiles (29.4% of patients);
dosing regimens and treatment duration (77 patients,
19.7%); and mechanism of action and indication (70
patients, 17.9%) (Figure 1). Results of binary logistic
regression indicated that being prescribed 3 new
drugs was a significant predictor of patients’ seeking
additional information about dosing regimen.
Prescribed diuretics were a significant additional
predictor of the same issue (Table 2). Moreover,
patients who were prescribed beta-blockers and sta-
tins were 3.5 times more likely to require information
about the treatment outcomes (Table 2). However,
when respiratory drugs were prescribed, 19% of
patients were interested in learning drug use (e.g.
practical aspects of the use of the inhalers).
Expectations
Approximately 50% of patients expected that the new
drug would control the symptoms of the health prob-
lem while 6% of patients expected a permanent solu-
tion while almost one quarter anticipated an
improvement of the quality of life (Figure 1). By using
binary logistic regression we determined that patients,
who were prescribed at least one drug for the alimen-
tary or musculoskeletal system, were 3.8–5.6 times
more likely to expect a permanent resolution of their
health problem (Table 2). Calcium channel blockers
were predictive of patients’ expectations that a newly
prescribed drug will better control the symptoms than
the previous therapy (Table 2).
Drug-related problems
In this study, 18% of patients experienced problems
with administration and dosing regimen during the
first weeks of treatment. Similarly, 27.3% of patients
experienced adverse drug reactions following drug
treatment initiation. The most frequent were gastro-
intestinal disturbances in 33, central nervous system in
14 patients, followed by cardiovascular adverse effects
in 10 patients. Statistical analysis showed that a higher
proportion of patients experienced practical problems
associated with inhaled corticosteroids when respira-
tory drugs were prescribed (Table 3). Additional results
are provided in Table 3.
Concerns
In the study, 32.5% of patients were mainly concerned
about the drugs’ safety profiles while 9.8% of patients
were worried about the duration of therapy.
Ineffectiveness was an issue for 3.1% of patients
Table 1. Examples of sub-categorizing patients’ answers.
Patient’s response Sub-category
‘Is this drug harmful if I use it for a long period?’ Side effects
‘Do I have to take medicines every day?’ Regimen
‘I expect that the drug will lower my LDL and total cholesterol level.’ Condition under the control
‘How to use these inhalators properly? My doctor told me, but I'd like to hear it again.’ Drug use
‘It seems that this drug is not helping me.’ Ineffectiveness
‘Is this life-long treatment?’ Duration
‘How to keep the drug properly? I heard that I could keep it in the fridge, is it true?’ Storage
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(Figure 1). When respiratory medicines were pre-
scribed, 12% of patients were worried about chronic
therapy aspects including forgetfulness, behaviour in
case of acute respiratory crisis, etc. Statistical analysis
results are given in Table 2.
Reasons to stop therapy
According to the results, manifested adverse drug
reactions (reported by 28.1% of patients), drug’s inef-
fectiveness (19.5%) and advice given by medical doc-
tors (16.1%) would be potential reasons for treatment
Figure 1. Number of patients’ answers concerning interests (knowledge); expectations; concerns; reasons to stop therapy.
Table 2. Statistically significant predictors of patients’ knowledge, expectations, concerns, reasons to stop therapy.
Category Cohort Sub-category Predictora OR 95%CI
Knowledge All patients
(n¼ 391)
Regimen 3 new drugs 4.31 1.52–12.21
Treatment outcome M 3.63 1.50–8.77
Patients prescribed C medicines
(n¼ 246)





























Patients prescribed C medicines
(n¼ 246)

























Patients prescribed C medicines
(n¼ 246)
Achieved control Beta blockers 4.10 1.26–13.43
aStatistically significant level:P<0.05,P<0.01,P< 0.001.
OR: odds ratio; 95%CI: 95% confidence interval; A, C, M, R, newly prescribed drugs for alimentary tract and metabolism, cardiovascular, musculoskeletal
system, respiratory system, respectively.
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termination (Figure 1). If a patient were to experience
an improvement in the treated condition, 5.9%
patients might stop taking the drug. Treatment discon-
tinuation due to financial reasons was reported by
4.4% of patients, mainly when musculoskeletal and
respiratory drugs were prescribed (12.5% and 7.9% of
patients, respectively). Accordingly, these patients
were approximately five and three times more likely to
stop the treatment due to financial issues (Table 2).
Pharmacist–patient consultation outcome
The patient–pharmacist consultation has been based
on patients’ needs, concerns or drug-related problems
stated in the SCCF. In total, 59.0% of patients agreed
that counselling with pharmacists improved their com-
prehension of the medication use. Moreover, pharma-
cists reported that 65.0% of the patients who reported
adverse drug reactions were referred to their medical
doctor while the pharmacist resolved the remaining
drug-related problems (such as a sore throat when
corticosteroids inhalers were used, gastrointestinal
tract disturbances, etc.) Non-adherence to therapy was
recognized in 12.2% of patients, and 45.2% of these
patients were referred to their medical doctor, while
the remaining patients were educated by pharmacist–-
patient interaction on the necessity of taking drugs as
prescribed. Approximately, 90% of the consultations




Our results suggest that patients with newly pre-
scribed medicines for treatment of chronic disease are
interested and willing to engage in the support
offered by the community pharmacists. During the first
weeks of therapy initiation, 18% of patients experi-
enced practical problems with drug use and 27% of
patients reported adverse drug reactions.
Consequently, pharmacists took an active role by
resolving 35% of adverse drug reactions reported by
patients and 54.8% of adherence issues. Pharmacists
referred the remaining patients to their medical doc-
tors due to potential/actual drug-related problems.
Strengths and limitations
The limitation of the study is the researchers’ interpre-
tations of patients’ answers and coding step as an
open-type question form was used. However, two
researchers who independently analysed the given
answers performed this procedure. There was no stat-
istical calculation of sample size. It is important to
highlight that predictors identified in our study (e.g.,
reason to stop the treatment with musculoskeletal and
respiratory drugs due to financial issues) may not com-
pletely reflect healthcare systems in other countries
where different co-payment schemes exist. Moreover,
it was up to the pharmacists’ discretion to provide
counselling. It would be useful to include therapy out-
comes because of pharmacists’ interventions to evalu-
ate the impact of the pharmaceutical care model at
the initiation of the long-term treatment.
Interpretation and relation to literature
This study is an extension and a supplement to the
previously performed studies in The Netherlands and
Bulgaria [1]. The distribution of patients’ answers in all
categories (Figure 1) is comparable with the results of
the studies performed in The Netherlands and Bulgaria
[1,2]. In our study, the most common issues raised by
patients were the drugs’ safety profiles (Figure 1) as
previously reported [1,2,7,12,17,22]. Patients were
interested not only in gaining more information but
they also had concerns regarding the adverse drug
reactions and 28.05% of patients reported that they
would discontinue the treatment if side effects would
appear.
As previously reported, dosing regimen and out-
come counselling are contributing to the high level of
adherence during long-term therapies [23,24]. Our
results indicate that three or more newly prescribed
drugs as well as prescribed diuretics (due to the
impact of the time of administration on daily routine
or overnight quality of sleep) are significant predictors
of patients’ interests in dosing regimen. The results of
the study suggest that patients are more likely to
require information on the treatment outcomes
when prescribed beta-blockers and statins, due to
post-myocardial infarction patients’ awareness of the
seriousness of their disease and worries about the
future cardiovascular events [25] as well as patients
prescribed musculoskeletal drugs as disease can limit
their everyday routine [26,27].
Patients prescribed with musculoskeletal or respira-
tory drugs have a higher probability of discontinuing
the treatment due to financial issues in Serbia
(Table 2). It is interesting to note that for most of
these drugs; patients’ cost sharing is on average 5–10
times higher than the basic additional fee for the reim-
bursement list of medicines. In analysed cohorts, 66%
of patients were prescribed drugs requiring an
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additional fee (up to 35 times greater than a basic
additional fee) upon dispensing. As previously
observed, this may lead to lower level of adherence
and consequently to treatment failure [17,28].
Furthermore, poor control was likely to be reported
by patients if three or drugs that are newer were pre-
scribed (with at least one for the cardiovascular sys-
tem). This poorly controlled drug use may be due to
patients’ subjective perception of the not easily recog-
nizable multiple symptoms (e.g., hypertension) [10].
Furthermore, patients on inhaled corticosteroid ther-
apy reported drug administration problems (Table 3).
These problems may be partially explained by cortico-
steroid phobia owing to lack of information, potential
side effects that patients are likely to encounter (such
as oral candidiasis, sore throat, hoarse voice), and pos-
sibly inadequate patients' inhalation techniques, all
leading to inappropriate drug use [10,15]. Hence our
results identify the patients who may require more
comprehensive pharmacist counselling when dispens-
ing drugs in the community pharmacies.
Implications for clinical practice
Patient-guided counselling allows more supplemental
questions by both patient and pharmacist, and a more
in-depth recognition of individual patients’ needs,
expectations, and concerns when prescribed new med-
icines for long-term treatments. Information about
adverse reactions to newly prescribed drugs for treat-
ment of chronic disease ought to be an integral part
of medicine management. Additionally, when patients
are prescribed three or more new drugs for treatment
of chronic disease, counselling on dosing regimen is
warranted. In contrast to multiple drugs regimen,
counselling is required whenever respiratory drugs
are introduced in the therapy. Frequent patient moni-
toring would be beneficial in the first few weeks
of treatment initiation, as patients may experience
drug-related problems. This study can be used to
discriminate delicately which patients require individ-
ual pharmacists’ attention and which specific aspects
should be covered during the critical first weeks when
new medicines are prescribed, so that long-term out-
comes can be achieved. Hence, these results should
be used to improve patient–pharmacists counselling.
Conclusion
Pharmacists are well positioned within a healthcare
system and should take a proactive role in the care of
patients with newly prescribed drugs for treatment of
chronic disease, aiming to ensure that patients’
expectations and needs are met, concerns are minimal,
that patients will adhere to the prescribed treatment,
and recognize/resolve drug-related problems during
the therapy initiation.
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